What is Bioptix?
Bioptix operates at the intersection of advanced molecular biology and clinical diagnostics, providing a comprehensive suite of reagents, assay kits, and specialized cell lines. The company serves a diverse clientele spanning academic research institutions, pharmaceutical giants, and clinical diagnostic laboratories. By focusing on high-quality, precision-engineered tools, Bioptix enables researchers to push the boundaries of cancer studies and diagnostic testing. Their market position is defined by a commitment to enhancing scientific throughput and improving patient outcomes through rigorous technological standards. As a key supplier in the life sciences supply chain, the company plays a pivotal role in supporting the infrastructure required for modern medical breakthroughs.
How much funding has Bioptix raised?
Bioptix has raised a total of $22.7M across 8 funding rounds:
Unspecified
$3.4M
Unspecified
$1.2M
Unspecified
$4.5M
Unspecified
$6.2M
Private Equity
$2.1M
Private Equity
$1.4M
Private Equity
$1.5M
Private Equity
$2.5M
Unspecified (2009): $3.4M with participation from Boulder Ventures
Unspecified (2010): $1.2M, investors not publicly disclosed
Unspecified (2011): $4.5M supported by Boulder Ventures
Unspecified (2013): $6.2M, investors not publicly disclosed
Private Equity (2014): $2.1M, investors not publicly disclosed
Private Equity (2014): $1.4M with participation from Rusnano, Boulder Ventures, and Remeditex
Private Equity (2015): $1.5M, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Key Investors in Bioptix
Boulder Ventures
A venture capital firm specializing in early-stage IT and biotech companies, with a strong track record of supporting innovation in the Colorado and Mid-Atlantic regions.
Rusnano
An investment group focused on the development and optimization of advanced technologies, including biotechnology and microelectronics, to enhance industrial capabilities.
Remeditex
A firm dedicated to accelerating the commercialization of early-stage biomedical research by providing capital and strategic guidance to biotechnology ventures.
What's next for Bioptix?
With the recent capital infusion, Bioptix is expected to prioritize the commercialization of its next-generation diagnostic platforms. The strategic roadmap likely includes scaling manufacturing capabilities to meet the rising demand for specialized PCR reagents and expanding its reach into emerging markets. Furthermore, the company is poised to deepen its collaborative efforts with pharmaceutical partners to streamline the drug discovery process. By maintaining a focus on innovation and operational excellence, Bioptix aims to solidify its status as an essential partner for organizations navigating the complexities of modern biotechnology and personalized medicine. The firm's growth trajectory suggests a continued emphasis on high-impact research tools that drive both scientific discovery and commercial success.
See full Bioptix company page
